Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers

Abstract

The aim of the present study was to compare the bioavailability of valacyclovir (CAS 124832-26-4; INN: valaciclovir) from two valacyclovir hydrochloride (CAS 214832-27-5) capsules (150 mg/capsule as test preparation and 150 mg/capsule commercially available original capsule of the drug as reference preparation) in 20 Chinese healthy male volunteers, aged between 20 and 27. The study was conducted according to an open, randomized, single blind, 2-way crossover study design with a washout phase of 7 days. Blood samples for pharmacokinetic profiling were taken up to 24 h post-dose. Valacyclovir hydrochloride is rapidly converted to acyclovir (CAS 59277-89-3) after oral administration, so the pharmacokinetics and bioequivalence of valacyclovir hydrochloride can be studied by determining the plasma concentration of acyclovir. Plasma concentrations of acyclovir were determined with a validated liquid chromatographytandem mass spectrometry (LC-MS/MS) method. The pharmacokinetic parameters of test and reference formulations were estimated as follows: the maximum plasma concentrations (C_max) were 2.04 ± 0.43 μg/mL and 2.01 ± 0.50 μg/mL; the median T_max were 1.1 ± 0.3 h and 1.0 ± 0.3 h; plasma elimination half-lives (t_1/2) were 2.94 ± 0.42 h and 2.85 ± 0.28 h. Values of AUC_0–t demonstrate nearly identical bioavailability of valacyclovir hydrochloride from the examined formulations. AUC_0–15 were 6.70 ± 1.26 μg · h/mL and 6.96 ± 1.25 μg · h/mL. Areas under the plasma concentration-time curve (AUC_0–∞ were 6.90 ± 1.30 μg · h/mL and 7.15 ± 1.31 μg · h/mL. Both primary target parameters, AUC_0–∞ and AUC_0–t were tested parametrically by analysis of variance (ANOVA) and relative bioavailabilities were 96.69 ± 7.89% for AUC_0–∞, 96.40 ±8.0% for AUC_0–15. Bioequivalence between test and reference preparation was demonstrated for both parameters, AUC_0–∞ and AUC_0–t. The 90% confidence intervals of the T/R-ratios of logarithmically transformed data were in the generally accepted range of 80–125%. It meant that the test formulation was bioequivalent to the reference formulation for valacyclovir hydrochloride.

Key words

Acyclovir - Antiviral drugs - CAS 59277-89-3 - CAS 124832-26-4 - CAS 214832-27-5 - Valacyclovir - Valacyclovir hydrochloride, bioequivalence, pharmacokinetics

• References

• 1 Jadhav AS, Pathare DB, Shingare MS. Development and validation of enantioselective high performance liquid chromatographic method for Valacyclovir, an antiviral drug in drug substance. J Pharm Biomed Anal. 2007; 43: 1568-72
• 2 Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res. 1995; 28: 281-90
• 3 Perry CM, Faulds D. Valaciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs. 1996; 52 (5) 754-72
• 4 O’Brien JJ, Campoli-Richards DM. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989; 37: 233-309
• 5 Prentice HG, Gluckman E, Powles RC, Ljungman P, Milpied NJF, Ranada JMF et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet. 1994; 343: 749-53
• 6 Garré B, Shebany K, Gryspeerdt A, Baert K, van der Meulen K, Nauwynck H et al. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Antimicrob Agents Chemother. 2007; 51: 4308-14
• 7 Acosta EP, Fletcher CV. Valaciclovir. Ann Pharmacother. 1997; 31 (2) 185-91
• 8 Phan DD, Chin-Hong P, Lin ET, Anderle P, Sadee W, Guglielmo BJ. Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an HPEPT1 inhibitor. Antimicrob Agents Chemother. 2003; 47: 2351-3
• 9 Landowski CP, Sun D, Foster DR, Menon SS, Barnett JL, Welage LS et al. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003; 306: 778-86
• 10 Reardon JE, Spector T. Acyclovir: Mechanism of antiviral action and potentiation of ribonucleotide reductase inhibitors. Adv Pharmacol. 1991; 22: 1-27
• 11 Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single and multiple dose administration to normal volunteers. Clin Pharmacol Ther. 1993; 54 (6) 595-605
• 12 Sould-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavalilability and metabolic disposition of valaciclovir, the l-valyl ester of acyclovir, following oral administrations to humans. Antimicrob Agents Chemother. 1995; 39 (12) 2759-64
• 13 Eksborg S, Pal N, Kalin M, Palm C, Söderhäll S. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir?. Med Pediatr Oncol. 2002; 38 (4) 240-6
• 14 Hara K, Suyama K, Itoh H, Nagashima S. Influence of ALDH2 genetic polymorphisms on aciclovir pharmacokinetics following oral administration of valaciclovir in Japanese end-stage renal disease patients. Drug Metab Pharmacokinet. 2008; 23 (5) 306-12
• 15 Jacobson MA, Gallant J, Wang LH, Coakley D, Weller S, Gary D et al. Phase I trial of valaciclovir, the L-valyl ester of aciclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 1994; 38: 1534-40
• 16 Landowski CP, Sun D, Foster DR, Menon SS, Barnett JL, Welage LS, Ramachandran C, Amidon GL. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003; 306: 778-86
• 17 US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry, Bioanalytical Method Validation 2001
• 18 Schulz HU, Steinijans VW. Striving for standards in bio-equivalence assessment:areview. Int J Clin Pharmacol Ther Toxicol. 1991; 29: 293-8
• 19 Gardner S. Bioavailability and bioequivalence requirements. Procedures for establishing a bioequivalence requirement. Fed Reg. 1977; 42: 1624-53
• 20 Note for Guidance on the Investigation of Bioavailability and Bioequivalence Committee for Proprietary Medicinal Products, CPMP/EWP/QWP/1401/98. London; 26 July 2001